Skip to content
  • About GRP
    • Why Choose Us
    • Leadership
    • Brochure
    • Careers
  • Countries
    • Canada’s Health Canada
    • United States’ FDA
    • Brazil
    • Mexico’s COFEPRIS
    • Europe’s EMA
    • Australia
    • China
    • Japan’s PMDA
    • Korea’s Ministry of Food and Drug Safety (MFDS)
    • Taiwan’s Food and Drug Administration (TFDA)
    • Singapore’s HSA
    • India’s CDSCO

    North America

    Canada

    United States of America

    Latin AMerica

    Brazil

    Mexico

    Europe

    European Union

    Australia

    Australia

    Asia

    China

    Japan

    South Korea

    Taiwan

    Singapore

    India

  • Services

    Medical Devices

    • Authorized Local Agent
    • Regulatory Intelligence
    • Regulatory Strategy
    • Regulatory Affairs
    • Product Registration
    • Medical Writing
    • Health Authority Consultation
    • Clinical

    Pharmaceuticals

    • Authorized Local Agent
    • Regulatory Intelligence
    • Regulatory Strategy
    • Regulatory Affairs
    • Product Registration
    • Regulatory Operations
    • Health Authority Consultation

    Nutraceuticals / Food Supplements

    • Authorized Local Agent
    • Regulatory Intelligence
    • Regulatory Affairs
    • Regulatory Strategy
    • Verification of Nutrient Claims
    • Verification of Health Claims

    Cosmetics & Personal Care Products

    • Authorized Local Agent
    • Regulatory Intelligence
    • Regulatory Affairs
    • Regulatory Strategy
    • Cosmetic Packaging and Labeling Review
    • Product Classification and Formulation Review

    Pharmacovigilance

    • Overview
    • GRP Pharmacoviglance Services

    Quality

    • Preparation for FDA Inspections
    • GMP Mockup Quality Audits
    • ISO 13485 Quality Audits
    • GCP Audits
    • cGTP Audits
    • GAP Analysis Audits
    • Foreign Manufacture Accreditation (FMA)
    • QA SOPs Development
  • Resource Center
    • Blog
    • Market Access Special Programs
    • Press Releases
    • White Papers
    • Case Studies
    • Videos
    • Presentations
    • Brochure
  • RI Platform
    • Japan Regulatory Intelligence (RI)
    • China (NMPA) Regulatory Intelligence
    • Brazil
    • Mexico Regulatory Intelligence (RI)
    • USA Regulatory Intelligence (RI)

    Japan

    • Health Authority
    • Medical Device
    • Pharmaceuticals
    • Clinical Trials
    • Cosmetics
    • Food Supplements

    China

    • Health Authority
    • Medical Device
    • Pharmaceuticals
    • Clinical Trials
    • Cosmetics
    • Food Supplements

    Brazil

    • Health Authority
    • Medical Device
    • Pharmaceuticals
    • Clinical Trials
    • Cosmetics
    • Food Supplements

    Mexico

    • Health Authority
    • Medical Device
    • Pharmaceuticals
    • Clinical Trials
    • Cosmetics
    • Food Supplements

    USA

    • Medical Device
    • Pharmaceuticals
    • Clinical Trials
    • Cosmetics
    • Food Supplements
  • Contact Us
  • About GRP
    • Why Choose Us
    • Leadership
    • Brochure
    • Careers
  • Countries
    • Canada’s Health Canada
    • United States’ FDA
    • Brazil
    • Mexico’s COFEPRIS
    • Europe’s EMA
    • Australia
    • China
    • Japan’s PMDA
    • Korea’s Ministry of Food and Drug Safety (MFDS)
    • Taiwan’s Food and Drug Administration (TFDA)
    • Singapore’s HSA
    • India’s CDSCO
  • Services
  • Resource Center
    • Blog
    • Market Access Special Programs
    • Press Releases
    • White Papers
    • Case Studies
    • Videos
    • Presentations
    • Brochure
  • RI Platform
    • Japan Regulatory Intelligence (RI)
    • China (NMPA) Regulatory Intelligence
    • Brazil
    • Mexico Regulatory Intelligence (RI)
    • USA Regulatory Intelligence (RI)
  • Contact Us
Menu
  • About GRP
    • Why Choose Us
    • Leadership
    • Brochure
    • Careers
  • Countries
    • Canada’s Health Canada
    • United States’ FDA
    • Brazil
    • Mexico’s COFEPRIS
    • Europe’s EMA
    • Australia
    • China
    • Japan’s PMDA
    • Korea’s Ministry of Food and Drug Safety (MFDS)
    • Taiwan’s Food and Drug Administration (TFDA)
    • Singapore’s HSA
    • India’s CDSCO
  • Services
  • Resource Center
    • Blog
    • Market Access Special Programs
    • Press Releases
    • White Papers
    • Case Studies
    • Videos
    • Presentations
    • Brochure
  • RI Platform
    • Japan Regulatory Intelligence (RI)
    • China (NMPA) Regulatory Intelligence
    • Brazil
    • Mexico Regulatory Intelligence (RI)
    • USA Regulatory Intelligence (RI)
  • Contact Us

Category: vaccine

Anvisa approves release of vaccine and medicine against monkey pox

Anvisa approves release of vaccine and medicine against monkey pox

Brazil’s Anvisa approves Anvisa regulates the use of self-tests for Covid-19

Brazil’s Anvisa approves resolution establishing requirements for registration, distribution, commercialization, and use of covid-19 self-tests.

Brazil’s Anvisa approves extending the use of CoronaVac to children and adolescents aged 6 to 17 years

The emergency use authorization granted this Thursday (01/20) is valid only for the age group 6 to 17 years old.

Brazil’s Anvisa identifies positive Covid-19 case in Brazilian passenger from South Africa

The Ordinance No.660/2021 It would impose restrictions on exceptional and specific restrictions, measures and requirements for entry into the country, due to the risks of contamination and dissemination of the SARS-CoV-2 coronavirus (covid-19).

Brazil’s Anvisa releases a new Adverse Event Notification Form

Brazil’s Anvisa introduces new tool enables faster and easier notification of drugs and vaccines.

Distribution Process of the Covid-19 vaccines in Brazil

From the lab to the arm: learn about the Ministry of Health’s Covid-19 vaccine trial in Brazil.

FioCruz reinforces the position adopted by Anvisa, EMA and WHO on vaccine safety

Confidentiality agreement between the two regulatory authorities confirms Anvisa’s recognition on the international scene.

Guideline for Importation Process of Vaccines in Brazil

Material organized by Procomex brings description about the vaccine importation process into Brazil.

Anvisa’s role in monitoring adverse events during immunization – Covid-19

Brazil’s EUA procedure assesses the suitability of Covid-19 vaccines for use during the current public health emergency to minimize.

Anvisa Approves Unanimously the Emergency Use of Vaccines

Brazil’s EUA procedure assesses the suitability of Covid-19 vaccines for use during the current public health emergency to minimize.

Anvisa is evaluating two requests for emergency use of vaccine

A guide prepared by Anvisa provides guidance to development companies on procedures for emergency use authorization of Covid-19 vaccines.

Brazil’s Pharmacovigilance: The Program of Risk Management and Pharmaceutical Technology of Vaccines

A guide prepared by Anvisa provides guidance to development companies on procedures for emergency use authorization of Covid-19 vaccines.

← older

COMPANY

  • About US
  • Leadership
  • Why Choose Us

useful links

  • Contact Us
  • Brochures
  • Resource Center

GRP Headquarters

550 Cochituate Road
Framingham,  01701, MA, USA
Tel : (+1 ) 781 - 672 -4200
Twitter Youtube Linkedin
  • Privacy Policy
  • Terms & Conditions
  • Cookies Policy
  • Other Policies

Copyright ©2023 Global Regulatory Partners

Contact Us!